Pharma Trademarks Inc. – Trademark Portfolio

Entity Type: 03

Pharma Trademarks Inc. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. Currently, 2 trademarks are registered and 2 are pending. Notable registered marks include DOLOBID and GABARONE. The owner is based in Cheyenne, WY.

1712 Pioneer Ave, Suite 496

Cheyenne, WY 82001

14 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

OPIRAM
OPIRAM
Abandoned 2024
GABARONE
GABARONE
Registered 2024
DOLOBID
DOLOBID
Registered 2023
PANMYCIN
PANMYCIN
Abandoned 2023
ORUVAIL
ORUVAIL
Abandoned 2022
MECLOMEN
MECLOMEN
Abandoned 2022
ANSAID
ANSAID
Abandoned 2021
GIAZO
GIAZO
Abandoned 2021
OMTRYG
OMTRYG
Abandoned 2021
HEXADROL
HEXADROL
Abandoned 2021

Trademark Classifications

Pharma Trademarks Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (14 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Pharma Trademarks Inc. have?

Pharma Trademarks Inc. has 14 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 pending, 10 abandoned.

What trademark classes does Pharma Trademarks Inc. file in?

Pharma Trademarks Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Pharma Trademarks Inc.'s most well-known trademarks?

Pharma Trademarks Inc.'s registered trademark portfolio includes well-known marks such as DOLOBID and GABARONE. These are among 2 currently registered trademarks in the portfolio.

What is Pharma Trademarks Inc.'s trademark registration success rate?

Pharma Trademarks Inc. has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 2 applications are pending review.